Therapy Areas: Hereditary Disorders
12 September 2018 - - FINCH 2, a global, randomised, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumat...
7 September 2018 - - US-based Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) has completed enrollment for the two Phase 3 studies of the next-generation corrector VX-659 in triple combination with te...
31 August 2018 - - US-based biotechnology company Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and UK-based genome analysis company Genomics plc have agreed to a three-year collaboration, extendable to ...
22 August 2018 - - US-based biotechnology company Vertex's Vertex Pharmaceuticals (Europe) Ltd. business has received the Pharmaceutical Benefits Advisory Committee's recommendation for Orka...
21 August 2018 - - US-based sweat testing specialist ELITechGroup Biomedical Systems has release the new FDA-cleared Macroduct Advanced Sweat Collection System, the company said.

Features...
20 August 2018 - - The US Food and Drug Administration approved Kalydeco (ivacaftor) to include use in children with cystic fibrosis ages 12 to ...